Valrubicin

Valrubicin

File:Valrubicin.svg
Clinical data
ATC code	L01DB09 (WHO)
Pharmacokinetic data
Protein binding	>99%
Identifiers
IUPAC name [2-oxo-2-[2,5,12-trihydroxy-4- [5-hydroxy-6-methyl-4- (2,2,2-trifluoroacetyl) amino-tetrahydropyran-2-yl] oxy-7-methoxy-6,11-dioxo-1,2,3,4-tetrahydrotetracen- 2-yl]-ethyl] pentanoate
CAS Number	56124-62-0
PubChem CID	41744
DrugBank	APRD00662
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C34H36F3NO13
Molar mass	723.644 g/mol

WikiDoc Resources for Valrubicin
Articles
Most recent articles on Valrubicin Most cited articles on Valrubicin Review articles on Valrubicin Articles on Valrubicin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Valrubicin Images of Valrubicin Photos of Valrubicin Podcasts & MP3s on Valrubicin Videos on Valrubicin
Evidence Based Medicine
Cochrane Collaboration on Valrubicin Bandolier on Valrubicin TRIP on Valrubicin
Clinical Trials
Ongoing Trials on Valrubicin at Clinical Trials.gov Trial results on Valrubicin Clinical Trials on Valrubicin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Valrubicin NICE Guidance on Valrubicin NHS PRODIGY Guidance FDA on Valrubicin CDC on Valrubicin
Books
Books on Valrubicin
News
Valrubicin in the news Be alerted to news on Valrubicin News trends on Valrubicin
Commentary
Blogs on Valrubicin
Definitions
Definitions of Valrubicin
Patient Resources / Community
Patient resources on Valrubicin Discussion groups on Valrubicin Patient Handouts on Valrubicin Directions to Hospitals Treating Valrubicin Risk calculators and risk factors for Valrubicin
Healthcare Provider Resources
Symptoms of Valrubicin Causes & Risk Factors for Valrubicin Diagnostic studies for Valrubicin Treatment of Valrubicin
Continuing Medical Education (CME)
CME Programs on Valrubicin
International
Valrubicin en Espanol Valrubicin en Francais
Business
Valrubicin in the Marketplace Patents on Valrubicin
Experimental / Informatics
List of terms related to Valrubicin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Valrubicin (N-trifluoroacetyladriamycin-14-valerate, Valstar®) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.

Dosage

800 mg weekly for 6 weeks

Side effects

• Blood in urine
• Incontinence
• painful or difficult urination
• Unusually frequent urination

Template:WH Template:WikiDoc Sources